Kindred Biosciences, Inc., a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs related to equine metabolic syndrome. It is also developing biologics programs, including KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) to treat newborn foals; and canine atopic dermatitis, an immune-mediated inflammatory, chronic skin disease related to allergies. In addition, the company engages in the development of other biologic product candidates, such as KIND-502 to treat allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a biologics scaffold technology. Further, it is developing anti-IL31, anti-IL17, and anti-IL4/13 sink antibodies for treating atopic dermatitis in dogs; anti-TNF antibody for inflammatory bowel disease in dogs; anti-IgE antibody for treating allergic diseases in dogs; anti-VEGF antibody for cancer in dogs; anti-CD20 for treating cancer and autoimmune diseases in dogs; and checkpoint inhibitors to treat cancer in dogs. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-701-7901
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees63
OptionableOptionable
Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
How were Kindred Biosciences' earnings last quarter?
Kindred Biosciences Inc (NASDAQ:KIN) released its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.01. View Kindred Biosciences' Earnings History.
When is Kindred Biosciences' next earnings date?
What price target have analysts set for KIN?
7 Wall Street analysts have issued 1 year target prices for Kindred Biosciences' shares. Their forecasts range from $16.75 to $25.00. On average, they anticipate Kindred Biosciences' stock price to reach $20.4375 in the next year. This suggests a possible upside of 88.7% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.
What is the consensus analysts' recommendation for Kindred Biosciences?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.
What are Wall Street analysts saying about Kindred Biosciences stock?
Here are some recent quotes from research analysts about Kindred Biosciences stock:
- 1. According to Zacks Investment Research, "Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. " (2/7/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of KIN and our 12-month price target of $19.00 per share. We derive our price target based on a risk-adjusted net present value analysis of projected product revenues through 2027 assuming a 10% discount rate and 3% terminal growth rate. We derive an rNPV of $605M for the pipeline products and add in $92M in cash and cash equivalents to arrive at a 12-month price target of $18.53 per diluted share, which we round to $19.00." (1/14/2019)
- 3. Cantor Fitzgerald analysts commented, ". Post positive top-line results from the company’s pilot effectiveness study of KIND-016, we reiterate our Overweight rating and raise our 12-month price target to $25 from $20. Our price-target increase is driven by an increased conviction about KIN’s antibody pipeline, which includes KIND-016, a fully caninized, high-affinity IL-31 monoclonal antibody for the treatment of atopic dermatitis in dogs, an IL4/IL13 product that is likely to readout in early 2019, and by a number of undisclosed antibody products that the company is working on but has not yet disclosed." (10/31/2018)
Has Kindred Biosciences been receiving favorable news coverage?
Media coverage about KIN stock has been trending somewhat negative this week, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kindred Biosciences earned a news impact score of -1.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Kindred Biosciences' key competitors?
Some companies that are related to Kindred Biosciences include Allakos (ALLK), Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV), TherapeuticsMD (TXMD), Clovis Oncology (CLVS), Uniqure (QURE), Corcept Therapeutics (CORT), Cambrex (CBM), Spectrum Pharmaceuticals (SPPI), Phibro Animal Health (PAHC), Esperion Therapeutics (ESPR), Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), Vanda Pharmaceuticals (VNDA) and Puma Biotechnology (PBYI).
Who are Kindred Biosciences' key executives?
Kindred Biosciences' management team includes the folowing people:
- Dr. Richard Chin, Co-Founder, CEO & Director (Age 52)
- Ms. Denise M. Bevers, Co-Founder, Pres, COO & Director (Age 52)
- Ms. Wendy K. Wee, Chief Financial Officer (Age 66)
- Dr. Hangjun Zhan, Chief Scientific Officer (Age 59)
- Ms. Katja Buhrer, VP of Corp. Devel. & Investor Relations
Who are Kindred Biosciences' major shareholders?
Kindred Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.44%), Dimensional Fund Advisors LP (4.08%), General American Investors Co. Inc. (1.33%), Northern Trust Corp (1.10%), Geode Capital Management LLC (1.00%) and Assenagon Asset Management S.A. (0.50%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.
Which institutional investors are selling Kindred Biosciences stock?
KIN stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Squarepoint Ops LLC, Bank of America Corp DE, B. Riley Financial Inc., General American Investors Co. Inc., Northern Trust Corp, MetLife Investment Advisors LLC and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Kindred Biosciences company stock in the last year include Raymond Townsend and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.
Which institutional investors are buying Kindred Biosciences stock?
KIN stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Dimensional Fund Advisors LP, Rhumbline Advisers, Granite Investment Partners LLC, BlackRock Inc., Teton Advisors Inc., Grassi Investment Management and Bank of New York Mellon Corp. View Insider Buying and Selling for Kindred Biosciences.
How do I buy shares of Kindred Biosciences?
Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kindred Biosciences' stock price today?
One share of KIN stock can currently be purchased for approximately $10.83.
How big of a company is Kindred Biosciences?
Kindred Biosciences has a market capitalization of $367.28 million. The biopharmaceutical company earns $-30,870,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Kindred Biosciences employs 63 workers across the globe.
What is Kindred Biosciences' official website?
How can I contact Kindred Biosciences?
Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]
MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
